Abstract
Several drugs and toxins have been shown to be associated with the development of pulmonary vascular hypertension. Pulmonary hypertension (PH) related to these factors has been classified as primary PH (PPH), currently referred to as idiopathic pulmonary arterial hypertension, because its morphological findings, clinical manifestations, hemodynamic measures, and pathological changes were reported to be similar to those of PPH. In 1998, a clinical classification of PH was proposed, the “Evian classification,” which was updated in 2003. According to the revised clinical classification of PH, this disease with identifiable risk factors is called “pulmonary arterial hypertension (PAH) associated with drugs and toxins”. However, some drugs can be associated with pulmonary veno-occlusive disease (PVOD), persistent PH of the newborn (PPHN), and newly recognized systemic disease, in which the histopathological findings are characterized by pulmonary arteriopathy with medial hypertrophy of muscular and elastic arteries, dilation and intimal atheromas of elastic pulmonary arteries, and right ventricular hypertrophy. Plexogenic arteriopathy can be seen with the exception of PAH of persistent fetal circulation. The identification of drugs and toxins as risk factors for PH poses a great challenge to both the physician and the epidemiologist. Drugs and toxins are categorized according to the strength of their association with PH and the probability of causal role. Table 1 summarizes the drugs and toxins considered in this chapter.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Simonneau G, Galiè N, Rubin LJ et al (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43:5S–12S
Gurtner HP (1985) Aminorex and pulmonary hypertension. A review. Cor Vasa 27:160–171
Follath F, Burkart F, Schweizer W (1971) Drug-induced pulmonary hypertension? Br Med J 1:265–266
Greiser E (1973) Epidemiologic studies on the relation between use of appetite depressants and primary vascular pulmonary hypertension. Internist (Berl) 14:437–442
Olivari MT (1991) Primary pulmonary hypertension. Am J Med Sci 302:185–198
Loogen F, Worth H, Schwan G, Goeckenjan G, Lösse B, Horstkotte D (1985) Long-term follow-up of pulmonary hypertension in patients with and without anorectic drug intake. Cor Vasa 27:111–124
Kay JM, Smith P, Heath D (1971) Aminorex and the pulmonary circulation. Thorax 26:262–270
Gaine SP, Rubin LJ, Kmetzo JJ, Palevsky HI, Traill TA (2000) Recreational use of aminorex and pulmonary hypertension. Chest 118:1496–1497
Douglas JG, Munro JF, Kitchin AH, Muir AL, Proudfoot AT (1981) Pulmonary hypertension and fenfluramine. Br Med J 283:881–883
Pouwels HM, Smeets JL, Cheriex EC, Wouters EF (1990) Pulmonary hypertension and fenfluramine. Eur Respir J 3:606–607
McMurray J, Bloomfield P, Miller HC (1986) Irreversible pulmonary hypertension after treatment with fenfluramine. Br Med J 292:239–240
Fotiadis I, Apostolou T, Koukoulas A, Michelacakis N, Kremastinos D (1991) Fenfluramine-induced irreversible pulmonary hypertension. Postgrad Med J 67:776–777
Atanassoff PG, Weiss BM, Schmid ER, Tornic M (1992) Pulmonary hypertension and dexfenfluramine. Lancet 339:436
Roche N, Labrune S, Braun JM, Huchon GJ (1992) Pulmonary hypertension and dexfenfluramine. Lancet 339:436–437
Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G (1993) Primary pulmonary hypertension and fenfluramine use. Br Heart J 70:537–541
Abenhaim L, Moride Y, Brenot F et al (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 335:609–616
Mark EJ, Patalas ED, Chang HT, Evans RJ, Kessler SC (1997) Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med 337:602–606
Strother J, Fedullo P, Yi ES, Masliah E (1999) Complex vascular lesions at autopsy in a patient with phentermine-fenfluramine use and rapidly progressing pulmonary hypertension. Arch Pathol Lab Med 123:539–540
Tomita T, Zhao Q (2002) Autopsy findings of heart and lungs in a patient with primary pulmonary hypertension associated with use of fenfluramine and phentermine. Chest 121:649–652
Connolly HM, Crary JL, McGoon MD et al (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337:581–588
Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L (2000) Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 117:870–874
Walker AM, Langleben D, Korelitz JJ et al (2006) Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J 152:521–526
Humbert M, Sitbon O, Chaouat A et al (2006) Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173:1023–1030
Souza R, Humbert M, Sztrymf B et al (2008) Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 31:343–348
Rich S, Shillington A, McLaughlin V (2003) Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary pulmonary hypertension. Am J Cardiol 92:1366–1368
Hervé P, Launay JM, Scrobohaci ML et al (1995) Increased plasma serotonin in primary pulmonary hypertension. Am J Med 99:249–254
Friström S, Airaksinen MM, Halmekoski J (1977) Release of platelet 5-hydroxytryptamine by some anorexic and other sympathomimetics and their acetyl derivatives. Acta Pharmacol Toxicol 41:218–224
Zheng Y, Russell B, Schmierer D, Laverty R (1997) The effects of aminorex and related compounds on brain monoamines and metabolites in CBA mice. J Pharm Pharmacol 49:89–96
Celada P, Martín F, Artigas F (1994) Effects of chronic treatment with dexfenfluramine on serotonin in rat blood, brain and lung tissue. Life Sci 55:1237–1243
Redmon B, Raatz S, Bantle JP (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337:1773–1774
Rothman RB, Redmon JB, Raatz SK, Kwong CA, Swanson JE, Bantle JP (2000) Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. Am J Cardiol 85:913–915
Rothman RB, Ayestas MA, Dersch CM, Baumann MH (1999) Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation 100:869–875
Lee SL, Wang WW, Fanburg BL (2001) Dexfenfluramine as a mitogen signal via the formation of superoxide anion. FASEB J 15:1324–1325
Blanpain C, Le Poul E, Parma J et al (2003) Serotonin 5-HT2B receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. Cardiovasc Res 60:518–528
Dempsie Y, Morecroft I, Welsh DJ et al (2008) Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice. Circulation 117:2928–2937
Weir EK, Reeve HL, Huang JM et al (1996) Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 94:2216–2220
Machado RD, Pauciulo MW, Thomson JR et al (2001) BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 68:92–102
Thomson JR, Machado RD, Pauciulo MW et al (2000) Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family. J Med Genet 37:741–745
Humbert M, Deng Z, Simonneau G et al (2002) BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 20:518–523
Chaouat A, Coulet F, Favre C et al (2004) Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 59:446–448
Weir EK, Obreztchikova M, Hong Z (2008) Fenfluramine: riddle or Rosetta stone? Eur Respir J 31:232–235
Cameron J, Waugh L, Loadsman T, White P, Radford DJ (1984) Possible association of pulmonary hypertension with an anorectic drug. Med J Aust 140:595–597
Nall KC, Rubin LJ, Lipskind S, Sennesh JD (1991) Reversible pulmonary hypertension associated with anorexigen use. Am J Med 91:97–99
Hagiwara M, Tsuchida A, Hyakkoku M et al (2000) Delayed onset of pulmonary hypertension associated with an appetite suppressant, mazindol: a case report. Jpn Circ J 64:218–221
Barst RJ, Abenhaim L (2004) Fatal pulmonary arterial hypertension associated with phenylpropanolamine exposure. Heart 90:e42
Thomas SH, Butt AY, Corris PA et al (1995) Appetite suppressants and primary pulmonary hypertension in the United Kingdom. Br Heart J 74:660–663
Abramowicz MJ, Van Haecke P, Demedts M, Delcroix M (2003) Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation. Eur Respir J 22:560–562
No authors listed (2004) Hidden amphetamines: from smoking cessation to diabetes. Prescrire Int 13:18–20
Boutet K, Frachon I, Jobic Y et al (2009) Fenfluramine-like cardiovascular side effects of benfluorex. Eur Respir J 33:684–688
Rafel Ribera J, Casañas Muñoz R, Anguera Ferrando N, Batalla Sahún N, Castro Cels A, Pujadas Capmany R (2003) Valvular heart disease associated with benfluorex. Rev Esp Cardiol 56:215–216
Evrard F, Dupuis M, Muller T, Jacquerye P (2008) Isolated pulmonary hypertension and pergolide. Rev Neurol 164:278–279
Hong Z, Smith AJ, Archer SL et al (2005) Pergolide is an inhibitor of voltage-gated potassium channels, including Kv1.5, and causes pulmonary vasoconstriction. Circulation 112:1494–1499
Fahlén M, Bergman H, Helder G, Rydén L, Wallentin I, Zettergren L (1973) Phenformin and pulmonary hypertension. Br Heart J 35:824–828
Kleiger RE, Boxer M, Ingham RE, Harrison DC (1976) Pulmonary hypertension in patients using oral contraceptives. A report of six cases. Chest 69:143–147
Townend JN, Roberts DH, Jones EL, Davies MK (1992) Fatal pulmonary venoocclusive disease after use of oral contraceptives. Am Heart J 124:1643–1644
Morse JH, Horn EM, Barst RJ (1999) Hormone replacement therapy: a possible risk factor in carriers of familial primary pulmonary hypertension. Chest 116:847
Martinez-Taboada VM, Rodriguez-Valverde V, Gonzalez-Vilchez F, Armijo JA (2004) Pulmonary hypertension in a patient with rheumatoid arthritis treated with leflunomide. Rheumatology 43:1451–1453
Jochmann N, Kiecker F, Borges AC et al (2005) Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report. Cardiovasc Ultrasound 3:26
Al-Zahrani H, Gupta V, Minden MD, Messner HA, Lipton JH (2003) Vascular events associated with alpha interferon therapy. Leuk Lymphoma 44:471–475
Dawson A, Elias DJ, Rubenson D et al (1996) Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepatopulmonary syndrome. Ann Intern Med 125:901–904
Belmatoug N, Launay O, Carbon C (1998) Pulmonary hypertension in type 1 Gaucher’s disease. Comité d’Evaluation du Traitement de la Maladie de Gaucher. Lancet 352:240
Younis TH, Alam A, Paplham P, Spangenthal E, McCarthy P (2003) Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma. Br J Haematol 121:191–192
Antonioli E, Nozzoli C, Gianfaldoni G et al (2005) Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma. Ann Oncol 16:1849–1850
Hattori Y, Shimoda M, Okamoto S, Satoh T, Kakimoto T, Ikeda Y (2005) Pulmonary hypertension and thalidomide therapy in multiple myeloma. Br J Haematol 128:885–887
Lafaras C, Mandala E, Verrou E et al (2008) Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study. Ann Oncol 19:1765–1769
Bentur L, Cullinane C, Wilson P, Greenberg M, O’Brodovich H, Silver MM (1991) Fatal pulmonary arterial occlusive vascular disease following chemotherapy in a 9-month-old infant. Hum Pathol 22:1295–1298
Vaksmann G, Nelken B, Deshildre A, Rey C (2002) Pulmonary arterial occlusive disease following chemotherapy and bone marrow transplantation for leukaemia. Eur J Pediatr 161:247–249
Joselson R, Warnock M (1983) Pulmonary veno-occlusive disease after chemotherapy. Hum Pathol 14:88–91
Knight BK, Rose AG (1985) Pulmonary veno-occlusive disease after chemotherapy. Thorax 40:874–875
Waldhorn RE, Tsou E, Smith FP, Kerwin DM (1984) Pulmonary veno-occlusive disease associated with microangiopathic hemolytic anemia and chemotherapy of gastric adenocarcinoma. Med Pediatr Oncol 12:394–396
Vansteenkiste JF, Bomans P, Verbeken EK, Nackaerts KL, Demedts MG (2001) Fatal pulmonary veno-occlusive disease possibly related to gemcitabine. Lung Cancer 31:83–85
Gagnadoux F, Capron F, Lebeau B (2002) Pulmonary veno-occlusive disease after neoadjuvant mitomycin chemotherapy and surgery for lung carcinoma. Lung Cancer 36:213–215
Lombard CM, Churg A, Winokur S (1987) Pulmonary veno-occlusive disease following therapy for malignant neoplasms. Chest 92:871–876
Trobaugh-Lotrario AD, Greffe B, Deterding R, Deutsch G, Quinones R (2003) Pulmonary veno-occlusive disease after autologous bone marrow transplant in a child with stage IV neuroblastoma: case report and literature review. J Pediatr Hematol Oncol 25:405–409
Rose AG (1983) Pulmonary veno-occlusive disease due to bleomycin therapy for lymphoma. Case reports. S Afr Med J 64:636–638
Swift GL, Gibbs A, Campbell IA, Wagenvoort CA, Tuthill D (1993) Pulmonary veno-occlusive disease and Hodgkin’s lymphoma. Eur Respir J 6:596–598
Salzman D, Adkins DR, Craig F, Freytes C, LeMaistre CF (1996) Malignancy-associated pulmonary veno-occlusive disease: report of a case following autologous bone marrow transplantation and review. Bone Marrow Transplant 18:755–760
Seguchi M, Hirabayashi N, Fujii Y et al (2000) Pulmonary hypertension associated with pulmonary occlusive vasculopathy after allogeneic bone marrow transplantation. Transplantation 69:177–179
Troussard X, Bernaudin JF, Cordonnier C et al (1984) Pulmonary veno-occlusive disease after bone marrow transplantation. Thorax 39:956–957
Hackman RC, Madtes DK, Petersen FB, Clark JG (1989) Pulmonary venoocclusive disease following bone marrow transplantation. Transplantation 47:989–992
Kuga T, Kohda K, Hirayama Y et al (1996) Pulmonary veno-occlusive disease accompanied by microangiopathic hemolytic anemia 1 year after a second bone marrow transplantation for acute lymphoblastic leukemia. Int J Hematol 64:143–150
Williams LM, Fussell S, Veith RW, Nelson S, Mason CM (1996) Pulmonary veno-occlusive disease in an adult following bone marrow transplantation. Case report and review of the literature. Chest 109:1388–1391
Shankar S, Choi JK, Dermody TS, Head DR, Bunin N, Iannone R (2004) Pulmonary hypertension complicating bone marrow transplantation for idiopathic myelofibrosis. J Pediatr Hematol Oncol 26:393–397
Capewell SJ, Wright AJ, Ellis DA (1984) Pulmonary veno-occlusive disease in association with Hodgkin’s disease. Thorax 39:554–555
Kramer MR, Estenne M, Berkman N et al (1993) Radiation-induced pulmonary veno-occlusive disease. Chest 104:1282–1284
Walsh-Sukys MC, Tyson JE, Wright LL et al (2000) Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 105:14–20
Manchester D, Margolis HS, Sheldon RE (1976) Possible association between maternal indomethacin therapy and primary pulmonary hypertension of the newborn. Am J Obstet Gynecol 126:467–469
Dalens B, Dechelotte P, Gaulme J, Raynaud EJ (1981) Maternal treatment with indomethacin and severe neonatal pulmonary hypertension. Arch Fr Pediatr 38:261–265
Loe SM, Sanchez-Ramos L, Kaunitz AM (2005) Assessing the neonatal safety of indomethacin tocolysis: a systematic review with meta-analysis. Obstet Gynecol 106:173–179
Herget J, Hampl V, Povýsilová V, Slavík Z (1995) Long-term effects of prenatal indomethacin administration on the pulmonary circulation in rats. Eur Respir J 8:209–215
Levin DL, Fixler DE, Morriss FC, Tyson J (1978) Morphologic analysis of the pulmonary vascular bed in infants exposed in utero to prostaglandin synthetase inhibitors. J Pediatr 92:478–483
Silvani P, Camporesi A (2007) Drug-induced pulmonary hypertension in newborns: a review. Curr Vasc Pharmacol 5:129–133
Reefhuis J, Rasmussen SA, Friedman JM (2006) Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. N Engl J Med 354:2188–2190
Källén B, Olausson PO (2008) Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 17:801–806
Fornaro E, Li D, Pan J, Belik J (2007) Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am J Respir Crit Care Med 176:1035–1040
Schaiberger PH, Kennedy TC, Miller FC, Gal J, Petty TL (1993) Pulmonary hypertension associated with long-term inhalation of “crank” methamphetamine. Chest 104:614–616
Chin KM, Channick RN, Rubin LJ (2006) Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 130:1657–1663
Rothman RB, Baumann MH (2007) Methamphetamine and idiopathic pulmonary arterial hypertension: role of the serotonin transporter. Chest 132:1412–1413
Murray RJ, Smialek JE, Golle M, Albin RJ (1989) Pulmonary artery medial hypertrophy in cocaine users without foreign particle microembolization. Chest 96:1050–1053
Russell LA, Spehlmann JC, Clarke M et al (1992) Pulmonary hypertension in female crack users. Am Rev Respir Dis 145:A717
Collins E, Hardwick RJ, Jeffery H (1989) Perinatal cocaine intoxication. Med J Aust 150(331–332):334
Devathasan G, Low D, Teoh PC, Wan SH, Wong PK (1984) Complications of chronic glue (toluene) abuse in adolescents. Aust N Z J Med 14:39–43
Kay JM (1994) Dietary pulmonary hypertension. Thorax 49:S33–S38
Posada de la Paz M, Philen RM, Borda AI (2001) Toxic oil syndrome: the perspective after 20 years. Epidemiol Rev 23:231–247
Castro García M, Posada de la Paz M, Díaz de Rojas F, Abaitua Borda I, Aonso Gordo JM, Tabuenca Oliver JM (1984) Pulmonary hypertension after toxic rapeseed oil ingestion. J Am Coll Cardiol 4:443
Alonso-Ruiz A, Calabozo M, Perez-Ruiz F, Mancebo L (1993) Toxic oil syndrome: a long-term follow-up of a cohort of 332 patients. Medicine 72:285–295
Abaitua Borda I, Philen RM, Posada de la Paz M et al (1998) Toxic oil syndrome mortality: the first 13 years. Int J Epidemiol 27:1057–1063
Gómez-Sánchez MA, Mestre de Juan MJ, Gómez-Pajuelo C, López JI, Díaz de Atauri MJ, Martínez-Tello FJ (1989) Pulmonary hypertension due to toxic oil syndrome. A clinicopathologic study. Chest 95:325–331
Kilbourne EM (1992) Eosinophilia-myalgia syndrome: coming to grips with a new illness. Epidemiol Rev 14:16–36
Tazelaar HD, Myers JL, Drage CW, King TE Jr, Aguayo S, Colby TV (1990) Pulmonary disease associated with L-tryptophan-induced eosinophilic myalgia syndrome. Clinical and pathologic features. Chest 97:1032–1036
Acknowledgement
The authors thank M. Humbert for his helpful comments and advice.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Bouillon, K., Moride, Y., Bensouda-Grimaldi, L., Abenhaim, L. (2011). Pulmonary Arterial Hypertension Secondary to Anorexigens and Other Drugs and Toxins. In: Yuan, JJ., Garcia, J., West, J., Hales, C., Rich, S., Archer, S. (eds) Textbook of Pulmonary Vascular Disease. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-87429-6_73
Download citation
DOI: https://doi.org/10.1007/978-0-387-87429-6_73
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-87428-9
Online ISBN: 978-0-387-87429-6
eBook Packages: MedicineMedicine (R0)